ClinicalTrials.gg
RecruitingNCT07061821HVGLDUpdated Jan 16, 2026

Evaluation of Left Ventricular Ejection Fraction Using an Accelerated Cardiac Cine-MRI Sequence With Deep Learning-based Image Reconstructions

An interventional study of accelerated cardiac cine-MRI sequence in Left Ventricular Ejection Fraction, Cardiac Magnetic Resonance Imaging and Deep Learning, sponsored by Centre Hospitalier Universitaire, Amiens. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-16.

Sponsored by Centre Hospitalier Universitaire, Amiens · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
61
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Left ventricular hypertrophy (LVH) is a common condition that may result from hypertension, hypertrophic cardiomyopathy, aortic valve stenosis, or certain metabolic disorders. Cardiac imaging is essential for diagnosis, prognostic assessment, and quantification of cardiac function. While transthoracic echocardiography remains widely used, it is limited by acoustic window dependence and inter-observer variability. Cardiovascular Magnetic Resonance (CMR) imaging currently serves as the reference standard for measuring left ventricular ejection fraction (LVEF), cardiac volumes, and tissue characterization. However, conventional cine-CMR sequences require repeated breath-holds, which are often challenging for elderly or dyspneic patients, generating respiratory motion artifacts that compromise image quality. Accelerated cine-CMR sequences with deep learning-based image reconstructions offer a promising alternative by significantly reducing acquisition time while preserving image quality. This study aims to evaluate whether these accelerated cine-CMR sequences provide LVEF measurements concordant with conventional cine-CMR sequences, with potential to improve patient comfort and reduce examination time.

02

Conditions studied

  • Left Ventricular Ejection Fraction
  • Cardiac Magnetic Resonance Imaging
  • Deep Learning
  • Image Reconstruction
  • Left Ventricular Hypertrophy

Keywords

  • Left Ventricular Hypertrophy
  • Left Ventricular Ejection Fraction
  • Cardiac Magnetic Resonance Imaging
  • Deep Learning
  • Image Reconstruction
03

In context

Hypertrophy, Left Ventricular

162 studies on the registry are indexed under Hypertrophy, Left Ventricular; 28 are open to participants now.

This study's planned enrollment of 61 is below the median of 100 across 97 interventional studies indexed under Hypertrophy, Left Ventricular.

Browse Hypertrophy, Left Ventricular studies →

Lead sponsor

Centre Hospitalier Universitaire, Amiens is the lead sponsor of 586 studies on the registry; 185 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient referred for cardiac MRI as part of the assessment or follow-up of left ventricular hypertrophy
  • Age ≥ 18 years old
  • Ability of the subject to understand and express his consent
  • Affiliation to the social security scheme

Exclusion criteria

Exclusion Criteria:

  • Severe obesity (>140 kg) preventing the patient from entering the scanner bore, which has a diameter of less than 70 cm
  • Age ≥ 18 years old
  • Person under guardianship or curators, or deprived of liberty
  • Pregnant or breastfeeding woman
  • Known allergy to gadolinium chelates
  • Claustrophobia
  • Any to MRI
  • Arrhythmia
  • Inability to hold breath for more than 10 seconds
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
61 participants (estimated)

Interventions

  • Otheraccelerated cardiac cine-MRI sequence

    Addition of an accelerated cardiac cine-MRI sequence with deep learning-based image reconstruction to the standard cardiac MRI protocol, performed during the same session

06

What researchers measure

Primary outcomes

  1. LVEF Difference between both sequences

    Value of the difference between the measurement of left ventricular ejection fraction (LVEF) obtained using the accelerated cardiac cine-MRI sequence with Deep Learning-based image reconstruction compared to the conventional cine-MRI sequence.

    Time frame: day 1

Secondary outcomes

  1. difference of end-diastolic volume of the left ventricle between both sequences

    Value of the difference between the measurements of end-diastolic volumes of the left ventricle obtained using the accelerated cardiac cine-MRI sequence with Deep Learning-based image reconstruction compared to the conventional cine-MRI sequence.

    Time frame: day 1

  2. difference of end-systolic volume of the left ventricle between both sequences

    Value of the difference between the measurements of end-systolic volumes of the left ventricle obtained using the accelerated cardiac cine-MRI sequence with Deep Learning-based image reconstruction compared to the conventional cine-MRI sequence.

    Time frame: day 1

  3. Differnce of measurement of the global longitudinal strain of the left ventricle between both sequences

    Value of the difference between the measurement of global longitudinal strain of the left ventricle obtained using the accelerated cardiac cine-MRI sequence with Deep Learning-based image reconstruction compared to the conventional cine-MRI sequence.

    Time frame: day 1

  4. Difference of the left ventricular mass between both sequences

    Value of the difference between the measurement of left ventricular mass obtained using the accelerated cardiac cine-MRI sequence with Deep Learning-based image reconstruction compared to the conventional cine-MRI sequence.

    Time frame: day 1

  5. diffrence of the maximal thickness of the left ventricle between both sequences

    Value of the difference between the measurement of maximal thickness of the left ventricle obtained using the accelerated cardiac cine-MRI sequence with Deep Learning-based image reconstruction compared to the conventional cine-MRI sequence.

    Time frame: day 1

  6. Difference of the acquisition time between both sequences

    Value of the difference in acquisition time between the accelerated cardiac cine-MRI sequence with Deep Learning-based image reconstruction and the conventional cine-MRI sequence

    Time frame: day 1

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07061821
Responsible party
Sponsor
First posted
Jul 11, 2025
Start date
Aug 5, 2025
Primary completion
Sep 2026 (estimated)
Completion
Sep 2026 (estimated)
Last update
Jan 16, 2026

Study contacts

Cédric Renard, MD
Contact
renard.cedric@chu-amiens.fr
33+3 22 08 75 37

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion